"一针治愈"白血病等肿瘤顽疾。 作者丨 杨婧雪 编辑丨 刘恒涛 图 源 丨 艺妙生物 2015 年，三个即将毕业的清华生物学博士，没有任何职场的经历， 闯进了极其烧钱、依赖资源、向 来 由大 药企统治的医药江湖。 促使这三人做出这一决定的，是当时海外学术界出现的颠覆性技术—— CAR-T 。艺妙生物创始人兼 CEO 何霆最早注意到这一技术——传统抗癌药能延长晚期患者两个月生存期已属不易，但 CAR-T 却可以 "一针治愈" 白血病。 何霆认为，十年后， CAR-T 一定会成为重要的治疗技术。在博士毕业之际，他说服两位同学，三人 达成了一致意见，创立艺妙生物。如今，十年过去，艺妙生物围绕 CAR-T ，已经打造了一个产品矩 阵，并拿下了华东医药 10 亿元销售合作大单，于 2025 年正式开启了科创板 IPO 的征程。 清华园中三剑客创业结盟 2014 年，还在清华大学癌症生物学实验室攻读博士学位的何霆，看到了几篇海外学术论文。论文中 记录了治愈白血病的最新成果：嵌合抗原受体 T 细胞免疫治疗（ CAR-T 治疗），可以让晚期白血 病患者实现一针治愈。 当时，医学界治疗癌症的主要方法，是通过手术、化疗和放疗来消 ...

Core Viewpoint - Beijing Yimiao Shenzhou Biopharmaceutical Co., Ltd. is advancing its IPO process on the Sci-Tech Innovation Board, having signed a counseling agreement with CITIC Securities on July 23 this year [2]. Company Overview - Founded in 2015, Yimiao Shenzhou focuses on innovative drug development using original research gene cell therapy for major diseases such as cancer and autoimmune diseases [2]. - The company has developed a one-stop platform for gene cell drug research and industrialization, with 7 clinical trial approvals in China and 1 in the United States for CAR-T new drugs [2]. Product Pipeline - The research pipeline includes treatments for hematological tumors such as lymphoma, leukemia, and myeloma, as well as solid tumors like liver cancer, gastric cancer, colorectal cancer, and melanoma [2]. - The CAR-T product IM19 targets relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) and has submitted a New Drug Application (NDA) in China, which has been accepted [3]. - IM96 is the only CAR-T candidate drug globally that has received clinical trial approval in both China and the United States, specifically targeting GUCY2C [4]. Market Position - IM19's innovative CAR molecular design and production process provide more specific therapeutic effects, significantly improving survival time and quality of life for r/r DLBCL patients, thus filling a market gap for domestically developed CAR-T therapies in China [3]. - IM96 has been approved for treating colorectal cancer in China, marking it as the first CAR-T candidate for this indication in the country [4]. Financing and Investment - Yimiao Shenzhou has completed a total of 10 financing rounds since its establishment, with investors including Foothill Ventures, Tsinghua x-lab, and several other venture capital firms and funds [4].